enlightenVue

enlightenVue

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15.2M

Overview

enlightenVue is a private, commercial-stage medical device company pioneering a novel single-use micro-endoscope platform. Its FDA 510(k)-cleared SurgiVue device combines a 2mm diameter with two working channels, aiming to reduce infection risk, lower procedural costs, and expand minimally invasive access to small body cavities. The company is leveraging the high-growth single-use endoscopy market segment, with a leadership team possessing strong commercial and clinical expertise to drive adoption in targeted surgical specialties.

OphthalmologyHepatobiliaryPulmonaryUrology

Technology Platform

SurgiVue™ single-use micro-endoscope platform featuring a 2mm outer diameter (industry's smallest), two working channels, flush ports, superior optics, and a patented expandable tip for combined diagnostic and therapeutic interventions.

Funding History

2
Total raised:$15.2M
Series A$12M
Seed$3.2M

Opportunities

The single-use endoscopy market is the highest growth segment in endoscopy, driven by infection control concerns and cost pressures.
EnlightenVue's 2mm platform can enable new minimally invasive procedures in small body cavities, potentially expanding the total addressable market beyond current standard-of-care techniques.

Risk Factors

Key risks include intense competition from large medtech firms and other startups in single-use endoscopy, the challenge of driving surgeon adoption and changing clinical practice, and the need to secure favorable reimbursement for a single-use device to prove its economic value to hospitals.

Competitive Landscape

EnlightenVue competes in the single-use endoscopy market against large players like Boston Scientific (SpyGlass™), Ambu, and Olympus, as well as other startups. Its primary differentiation is the combination of the industry's smallest 2mm diameter with dual working channels for therapy, targeting a niche of ultra-minimally invasive procedures not well addressed by current offerings.